Enliven Posts Loss Beat and Cash Surge
Enliven Therapeutics (NASDAQ:ELVN), a clinical-stage biotechnology company focused on cancer therapies, reported its second quarter 2025 results on August 13, 2025. The release highlighted a net loss per share of $(0.49) for Q2 2025 (GAAP), a result that modestly beat the analyst estimate of $(0.54). The most notable news came from its advancing oncology pipeline: the lead program ELVN‑001 in chronic myeloid leukemia (CML) showed clinical results that exceeded historical benchmarks, with a 32% major molecular response (MMR) rate by 24 weeks as of April 28, 2025, in the ENABLE Phase 1 clinical trial, compared to historical MMR rates of 24% and 25% for asciminib in prior Phase 1 and Phase 3 trials, respectively. In addition, the company’s balance sheet improved sharply after a $230 million equity raise in Q2 2025, bringing cash and securities up to $490.5 million as of June 30, 2025. Overall, the quarter demonstrated clinical progress paired with ongoing financial losses, but also a strengthened cash position to support future development.
Source: Analyst estimates for the quarter provided by FactSet.
Enliven Therapeutics develops targeted cancer therapies with a current focus on two investigational drugs. The first, ELVN-001, is a tyrosine kinase inhibitor that targets the BCR-ABL gene for chronic myeloid leukemia, a form of blood cancer. The second, ELVN‑002, is a HER2 inhibitor for cancers driven by alterations in the HER2 gene, including certain breast, non-small cell lung, and colorectal cancers.
Source Fool.com
